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Abstract The endothelin receptors, ET A and ETB, are G pro- 
tein-coupled receptors (GPCR) that show distinctively different 
binding profiles for the endothelin peptides and other ligands. We 
recently reported that Tyr 129 in the second transmembrane r gion 
(FM2) of the ET A receptor was critical for subtype-specific li- 
gand binding [Krystek, S.R. et al. (1994) J. Biol. Chem. 269, 
12383-123861. Receptor models indicated that aspartic acids lo- 
cated one helical turn above (Asp 133) and below (Asp 126) Tyr 129 in 
ET A had their side chains directed toward the putative binding 
cavity. Similarly in ETa, Asp 147 and Asp ~s4 are located one turn 
below and above His ~5°, the residue that corresponds to Tyr ~zg. 
Asp 126 in ET A and Asp 147 in ETB correspond to the highly con- 
served aspartate present in TM2 of many GPCR that has fre- 
quently been shown to be crucial for agonist efficacy. Mutagene- 
sis of Asp ~26 of the human ET A receptor to alanine resulted in an 
unaltered affinity for ET-1, a 160-fold increase in ET-3 affinity 
and a decrease in affinity for the ETA selective naphthalenesul- 
tonamide, BMS-182874. ET-1 activation of phospholipase C was 
abolished. In addition, despite the gain in binding affinity, ET-3 
iailed to activate phospholipase C, suggesting that Asp 126 is re- 
quired for signal transduction. Mutagenesis of Asp j33 to a|anine 
indicated that it was critical only for the binding of BMS-182874. 
In the ET B receptor, mutation of His 15° to alanine or tyrosine 
indicated that it plays a minor role in ET B subtype-selective ligand 
binding; mutation of the aspartates in TM2 of ET a did not alter 
ligand binding. As in the Asp126Ala ET A variant, ET-1 and ET-3 
failed to increase intracellular levels of inositol phosphates in the 
~sp~47Ala ET~ mutant. Taken together, these data support the 
hypothesis that Asp ~26 and Asp 133 flanking Tyr m in TM2 of the 
ET A receptor play a role in defining ET A subtype-selective ligand 
binding but Asp 147 and Asp ~54 that flank the His ~5° in TM2 of the 
ETa receptor do not. Furthermore, these data indicate that Asp ~26 
in ETA and Asp 147 in ET B are important for transmembrane 
~ignaling via phospholipase C. 
g~ey words: Endothelin receptor; G protein-coupled receptor; 
',;ite-directed mutagenesis; Radioligand binding; Molecular 
nodeling; Phospholipase C 
I. Introduction 
Endothelins (ETs) are a family of peptides that mediate di- 
*Corresponding author. Fax: (1) (609) 252 6964. 
4bbrev&tions: TM2, second transmembrane r gion; ET, endothelin: 
IP, inositol phosphate; PLC, phospholipase C.
verse and potent biological activity in mammals through at 
least two distinct heptahelical G protein-coupled, cell surface 
receptors. The ETA subtype binds ET-1, the cyclic pentapeptide 
antagonist BQ-123, and the naphthalenesulfonamide antago- 
nist, BMS-182874, preferentially, whereas ET B binds ET-1, ET- 
3 and sarafotoxin $6c with approximately equal affinity [1-4]. 
Ro 46-2005 and Ro 47-0203 are pyrimidinyl naphthalenesul- 
fonamide antagonists that bind both receptor subtypes with 
equal affinity [5,6]. SB 209670 is an indanecarboxylic a id that 
binds ET A and ET B receptors with high affinity [7]. Due to the 
potent biological activities of the ET peptides, inhibition of 
their action through receptor antagonism has been proposed as 
a point for therapeutic ntervention i  numerous cardiovascu- 
lar diseases. 
Elucidation of receptor amino acids involved in ligand bind- 
ing and signal transduction is critical to understanding the 
mechanism of l igand-receptor-G protein interactions and may 
facilitate drug design. Evidence from chimeric ETA/ETa recep- 
tors indicates that transmembrane regions 1,2, 3, and 7 [8] and 
the first extracellular loop [9] may contain a binding site for 
BQ-12Y Takasuka et al. [10] reported that a 29 amino acid 
segment of the ET B N-terminus adjacent to the first transmem- 
brane region was important for ET-1 binding while Zhu et al. 
[11] reported that the lysine in TM3 of ETB was important for 
ET isopeptide binding and critical for sarafotoxin $6c binding. 
Finally, Adachi et al. [12] suggested that Lys ~4° of the ET A 
receptor is important for ET-1 binding. This residue is thought 
to be located at or near the C-terminus (extracellular side) of 
TM2. Recently, we and others reported that Tyr 129 in TM2 of 
the ET A receptor is critically involved in subtype-selective li- 
gand binding [13,14]. Mutation of Tyr ~29 to alanine or to histid- 
ine, the corresponding amino acid in ET a, resulted in a binding 
profile characteristic of an ETa receptor. In addition, this rep- 
resented one of the first indications that amino acids in the 
transmembrane regions are in contact with ET isopeptides as 
well as non-peptidic ligands [11,13-14]. 
Inspection of the sequence of TM2 in the human ET A recep- 
tor indicated that there are two aspartate residues flanking 
TyrL29; one is a turn above (Asp ~33) and the other is a turn below 
(Asp ~26) in the transmembrane h lix. A similar configuration is
present in ETB, with Asp 147 and Asp ~54 flanking His 15°. The 
Asp 1~6 in ETA, or Asp t47 in ETa, is conserved in many GPCR 
[15] and has been shown to be important in agonist binding 
and/or signal transduction i several receptors [16 20]. Accord- 
ing to our computer generated three-dimensional model of the 
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ET A receptor and our previous studies of Tyr ~29 in the ETA 
subtype-selective ligand binding, we hypothesized that the side 
chains of these aspartates are directed toward the putative 
binding cavity and may be involved in ligand binding and G 
protein-coupled signaling. To test these hypotheses and to in- 
vestigate the role of the aspartate-tyrosine-aspartate and aspar- 
tate-histidine-aspartate helical turns in subtype-selective ligand 
binding, Asp~26Ala and AspJ33Ala ET A mutants, as well as 
Asp147Ala and Asp~54Ala ET a mutants, were prepared and the 
binding affinities of a panel of ET receptor ligands were evalu- 
ated. Phosphoinositide turnover was measured in Asp126Ala 
and AspJ47Ala mutants to assess agonist efficacy. We show here 
that mutation of Asp ~26 to alanine causes an increase in the 
affinity of the ETa selective agonist, ET-3, and a decrease in the 
affinity of the ET A selective antagonist, BMS-182874. Mutation 
of Asp 133 to alanine only causes a decrease in the affinity of 
BMS-182874. In contrast, mutagenesis of the analogous aspar- 
tates in ETa, Asp 147 and Asp t54, failed to affect the ETB receptor 
binding profile, demonstrating that TM2 is important in defin- 
ing ETA but not ETa subtype selective ligand binding. In addi- 
tion, we show that phospholipase C activation is abolished in 
the AspJ26Ala ET A and Asp147Ala ET B mutants, indicating that, 
despite their differing importance in ligand binding, these resi- 
dues play a critical role in transmembrane signaling in both 
receptor subtypes. 
2. Materials and methods 
2.1. Materials 
Restriction enzymes and DNA modifying enzymes were from 
Promega (Madison, WI). The pACYC184 vector was obtained from 
New England BioLabs (Beverly, MA); the pCDM8 vector was from 
Invitrogen (San Diego, CA). The Transformer site-directed mutagene- 
sis system was obtained from Clontech (Palo Alto, CA). The Muta- 
Gene Phagemid in vitro Mutagenesis kit was obtained from BioRad 
(Hercules, CA). COS-7 cells were obtained from ATCC (Rockville, 
MD); tissue culture reagents and Lipofectamine were from Life Tech- 
nologies, Gibco/BRL (Gaithersburg, MD). [n25I]ET-1 (2,200 Ci/mmol) 
was obtained from DuPont NEN (Boston, MA), ET-I, ET-3 and 
sarafotoxin $6c from Peninsula Labs. Other biochemical reagents were 
obtained from Sigma (St. Louis, MO). 
2.2. Model building 
The construction ofthe ET A and ETB receptor models was performed 
as described previously [13]. Briefly, sequences of the receptor subtypes 
were aligned and the transmembrane r gions identified by pairwise 
comparisons based on hydrophobicity conservation. The putative 
transmembrane sequences were then threaded through a helix bundle 
which was derived from the coordinates of bacteriorhodopsin [21]. For 
this model the kinks found in the bacteriorhodopsin helices were re- 
moved and the helices were kinked based on the location of prolines 
in the ET receptor sequences. Geometry of the new seven helix bundle 
was refined as described [13]. Molecular modeling was conducted with 
INSIGHT and DISCOVER (Biosym Technologies, San Diego, CA) 
performed on a Silicon Graphics 4D/440 work station. Model analysis 
and display was conducted interactively using GRASP [22]. 
2.3. Mutagenesis 
Site-directed mutagenesis of the human placental ET A receptor [23] 
was conducted in our laboratory according to Deng and Nickoloff [24] 
and has been described elsewhere [13]. Mutagenesis of the human pla- 
cental ETB receptor [25] was conducted according to Kunkel [26]. 
Briefly, the ET B cDNA in pCDM8 was grown in the dut-ung- CJ236 
strain of E. coli, resulting in DNA carrying anumber of uracil contain- 
ing nucleotides in place of thymine, and single stranded DNA was 
isolated. A mutagenic oligonucleotide was annealed to the uracil con- 
taining single stranded template and the complementary strand was 
synthesized in vitro. When this double stranded DNA was transformed 
into dut+ung ÷MV1190 £ coli, the uracil containing strand was inac- 
tivated and the non-uracil containing, presumably mutant, strand was 
replicated. Mutant plasmids were initially identified by restriction anal- 
ysis and subsequently verified by sequencing the entire cDNA insert 
using the dideoxy sequencing method of Sanger et al. [27]. 
2.4. Receptor expression and binding 
Wild-type and mutant ET A and ET B receptor cDNAs were trans- 
fected into COS-7 cells using the polycationic lipid Lipofectamine ac- 
cording to the manufacturer's in tructions. COS-7 cells were routinely 
maintained in a growth medium of Dulbecco's modified essential me- 
dium (DMEM) containing 10% fetal bovine serum (FBS), penicillin 
(100 U/ml) and streptomycin (100 mg/ml). Transfection of COS-7 cells 
with a CMV/c~gal plasmid indicated a transfection efficiency of 5-20%. 
Cells were harvested 48-72 h after transfection and membranes were 
prepared as previously described [!3]. [~251]ET-I (50 pM) binding assays 
were performed as described previously [2] with specific binding defined 
in the presence of 100 nM ET-1. Data were analyzed by iterative curve 
fitting to a one binding site model. 
2.5. Measurement of phosphoinositide turnover 
COS-7 cells were seeded in 6-well plates (1 3 × 104 cells/well) in 
growth medium, and transfected as described above. Two to six hours 
following removal of transfection reagents, cells were labeled with 
[3H]myoinositol (8/ICi/ml) for 48-72 h. Cell monolayers were washed 
and incubated for 15 min in DMEM containing 20 mM LiCI and 0.1% 
bovine serum albumin. Cells were treated with ET-1 for 15 min and the 
media removed. Boiling EDTA (2 mM) was added to the cell mono- 
layer to disrupt cell integrity and release soluble inositol phosphate (IP). 
The resulting mixture was applied to a Dowex AG 1 × 8 anion exchange 
column and total IP was collected as described [28]. Eluant was counted 
in a Packard Tri-Carb 4640 scintillation counter at 40% efficiency. As 
a control for expression efficiency, specific [t25I]ET-1 binding (50 pM) 
was assessed concomitantly in COS-7 cells transfected with wild-type 
or mutant cDNA. Following the binding reaction, the cells were washed 
and transferred in 500/,tl of 0.5 N NaOH to a Packard Gamma counter 
for measurement of radioactivity. 
2.6. Statistical analysis 
Data are expressed as mean _+ standard error (S.E.) from three or 
more determinations. 
3. Results 
3.1. Binding to the A~p126Ala nd AsplJ3Ala ET  A receptor 
mutants 
Previous results with Tyr ~29 ETA receptor mutants [13] indi- 
cated that TM2 contributes to 'fine selectivity' of ligand binding 
to ET receptors. Based on the same ETA receptor model, two 
aspartate residues located approximately one helical turn above 
and below the Yyr 129 (Fig. 1A), are oriented in a manner similar 
to the tyrosine with their side chains directed toward the puta- 
tive ligand binding pocket (Fig. 1B). Asp 133 and Asp ~z6 are 
postulated to be approximately six and thirteen amino acid 
residues from the extracellular surface respectively. Alanines 
were substituted at each position and the resulting ETA receptor 
mutants, Asp126Ala and Asp~33Ala, were expressed in COS-7 
cells. The affinity of peptidic agonists and antagonists and 
non-peptidic antagonists for the mutant receptors was com- 
pared to that for wild-type ET A and ET B receptors. Based on 
energetic riteria, ten-fold or greater alterations in affinity from 
control were generally considered relevant [13,29]. Inhibition of 
specific [~251]ET-1 binding in membranes from transiently trans- 
fected COS-7 cells indicated that the affinity of ET-1 and ET-2 
were not altered by either the Asp~26Ala or Asp~33Ala mutations 
(Table 1), suggesting that the mutant receptors have not under- 
gone a general or large scale structural rearrangement. How- 
ever, the affinity of ET-3 for the AsplZ6Ala ET A receptor was 
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Fig. 1. Human ET A and ETB receptor models and corresponding amino acid sequences. Panel A: primary structure of human (h), bovine (b), rat 
(r) and porcine (p) ETA and ETa receptor sequences corresponding to predicted TM2 (indicated by the boxed residues). Numbering is according to 
the ETA receptor. Panel B: comparison of the superimposed models of the second TM2 of the ET A and ETB receptors. Shown is the least-squares 
superposition (of backbone atoms) for ET A and ET B displayed using ribbon representation forbackbone atoms of transmembrane region 7 (TM7), 
2 (TM2) and 3 (TM3). The aspartates and tyrosine/histidine residues in TM2 of ETA/ET B are displayed as well as Lys166/Lys (ETA/ETB) as a point 
of reference. The insert to panel B shows an axial view of the helices with side chains directed towards the putative ligand binding cavity. 
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Fig. 2. Effects of ET-1 and ET-3 on inositol phosphate accumulation i COS-7 cells expressing the wild-type and mutant ETA receptors. Panel A: 
COS-7 cells expressing the wild-type (solid symbols and lines) or AspJ26Ala (open symbols and dashed lines) ETA receptors were treated with increasing 
concentrations of ET-1 (circles) and ET-3 (triangles) for 15 rain. IP production was measured as described in section 2. Results are representative 
of three similar experiments and data points are the mean of duplicate determinations. Panel B: comparison of expression levels of wild-type and 
Asp126Ala ET A receptors in transiently transfected COS-7 cells. Specific [~251]ET-1 (50 pM) binding was determined in the absence and presence of 
100 nM ET-1. Data are expressed as the mean + S.E.M. of specific [125I]ET-I binding in three xperiments and were normalized to percent of wild-type 
levels. 
improved approximately 160-fold while the affinity of BMS- 
182874 decreased 20-fold (Table 1). Since ET-3 is approxi- 
mately 1,000-fold selective for the ETa receptor subtype and 
BMS- 182874 is approximately 1,000-fold selective for the ETA 
receptor subtype [4], these findings upport he hypothesis that 
Asp 126 plays a role in subtype selective ligand-receptor interac- 
tions. 
In contrast to the Aspm26Ala binding profile, ligand affinities 
for the Asp133Ala ETA mutant were largely unchanged from 
wildtype values with the exception of that for BMS-182874 
(Table 1). The binding affinity (IC50) for this antagonist de- 
creased 70-fold from 340 nM to 25/JM. 
3.2. Effects of mutation of Asp 126 on ETA-mediated 
phosphoinositide turnover 
Recombinant wild-type ETA receptors tably expressed in 
CHO cells activate phospholipase C (PLC) as assessed by meas- 
urements of intracellular IP accumulation [1,30]. Previous in- 
vestigations demonstrated that the conserved aspartate residue 
in TM2 (corresponding to Asp 126 in ETA) of the ~2-adrenergic 
[16], fl2-adrenergic [l 9], angiotensin AT 1 [ 18], lutropin [17] and 
opioid [20] receptors i crucial to signaling by agonist occupied 
receptors. Thus, the effect of alanine substitution for Asp 126 on 
PLC activation was examined. COS-7 cells transfected with the 
recombinant wild-type receptor or the AsplE6Ala variant were 
treated with increasing concentrations of ET-1. Cells trans- 
fected with wild-type ET A responded to ET-1 treatment with 
a concentration-dependent increase in total IP accumulation 
(ECs0 = 1 + 0.6 nM). However, the IP response to ET-1 was 
abolished in Asp126Ala transfected cells (Fig. 2A). The ablation 
of the IP response was not due to differences in receptor expres- 
sion because concomitant measurement of specific [125I]ET-1 
binding to wild-type and Asp126Ala transfected cells was similar 
(Fig. 2B). 
Given the 160-fold increase in ET-3 binding affinity for the 
Asp~26Ala ETA receptor, it was of interest o determine if this 
ETB-selective agonist could activate PLC. As shown in Fig. 2A, 
ET-3 produced a concentration-dependent increase in IP accu- 
mulation in cells transfected with wild-type ETA cDNA. The 
estimated ECs0 agrees with the IC50 value for ET-3 at the wild- 
type ETA receptor (ECs0 -- 800 nM; IC50 = 820 nM). However, 
ET-3 concentrations up to 1/JM failed to elicit an increase in 
intracellular IP levels above basal evels in COS-7 cells express- 
ing the Asp126Ala ETA variant where the IC50 for ET-3 im- 
proved to 5 nM. Thus, the gain in ET-3 binding affinity ob- 
served in the Asp~26Ala mutant did not result in a gain in 
ET-3-induced functional activity. 
3.3. Binding to Asp]4ZAla, His15°Ala, HiJ~°Tyr, and Asp154Ala 
ETs mutants 
As it became clear that TM2 in ETA played an important role 
in l igand-receptor-G protein interactions, the question arose 
as to whether the corresponding region in ET~ played a similar 
role. Examination of TM2 (Fig. 1A) of all currently cloned ETA 
Table 1 
Inhibition of specific [125I]ET-1 binding (50 pM) to AsplZ6Ala nd Asp133Ala ET A receptor mutants 
Agent Wild-type Asp126Ala AspmAla Wild-type 
ET A ETA ET A ETa 
ET-1 0.4 + 0.2 0,2 + 0.06 0.8 + 0.12 0.2 + 0.0 
ET-2 0.4 + 0.04 1.8 + 0.2 1.6 + 0.2 0.2 + 0.0 
ET-3 820 + 260 5.0 + 1.2 600 + 40 0.4 + 0.2 
$6c 29,000 + 4,000 12,100 _+ 1,700 6,600 + 320 0.3 + 0.I 
BQ-123 40 + 6 320 _+ 40 40 + 1 66,000 + 2,400 
BMS-182874 340 + 60 7,600 + 200 25,000 + 2,200 110,000 + 27,000 
Ro 47-0203 20 + 4 40 + 5 60 + 6 160 _+ 40 
Values are inhibition constants (IC50) in nM+ S.E.M. (n-> 3). Binding to the wild-type ET A and ETa receptors i  shown for comparison. 
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I'ig. 3. Effects of ET-I and ET-3 on inositol phosphate accumulation in COS-7 cells expressing the wild-type and mutant ET B receptors. Panel A: 
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,rod ET B receptors hows a single major non-conservative 
amino acid difference: Tyr 129 in ETA is His ~5° in ETB. All other 
:,equence differences are conservative r placements (ETA/ETB: 
lle128/Leu, Vall3°/Ile, Val131/Ile, Leu134/Ile) except for AlallT/Ile 
md Val138/Thr. Wal L38 of human ET A and Thr 159 in human ET B 
are of similar size while both Ala 117 and the corresponding ETB 
amino acid, Ile 138, are neutral, hydrophobic, aliphatic amino 
acids. Thus, both of these replacements can also be considered 
:onservative. Therefore, except for the tyrosine/histidine diver- 
gence one might expect he configuration f side chains in TM2 
to be similar in ETA and ETB. Interestingly, the aspartic acids 
~n TM2 of ETA (Asp 126 and Asp133), hypothesized to be facing 
the putative binding cavity, are conserved in ETB (Asp 147 and 
~.sp 154) (Fig. 1B). These considerations suggested that it might 
be informative to mutate the histidine and aspartate residues 
~n TM2 of ET~ to alanine. In addition, His ~5° was mutated to 
tyrosine, the amino acid present in the ETA receptor. 
Compared to the wild-type ET B receptor, ligand affinities to 
the Asp~54Ala and AsplaVAla ETB mutants did not show greater 
than 10-fold changes (Table 2). On the other hand, when His ~5° 
was mutated to alanine, the binding affinity for sarafotoxin $6c 
decreased 30-fold from 0,3 nM to 8 nM. Moreover, mutation 
of this histidine residue to tyrosine led to a decreased affinity 
of 10- to 200-fold for ET-3 and sarafotoxin $6c respectively. 
Thus, as the amino acid at position 150 of TM2 became more 
ETA-like, the affinity for ETB selective peptides was reduced. 
Interestingly, binding of the ETA/ET B non-selective sulfona- 
mide Ro 47-0203 decreased approximately 10-fold in the 
His~5°Ala mutant. These findings are consistent with the sugges- 
tion that His Ls° in TM2 of ETB is involved in high affinity 
binding of the ET~ selective agonists, ET-3 and sarafotoxin $6c, 
and provides ome interaction for the non-selective antagonist 
Ro 47-0203. 
3.4. Effects of mutation of Asp 147 on ETB-mediated 
phosphoinositide turnover 
Despite the lack of effects that mutation of Asp 147 had on 
agonist binding affinity, it was of interest o determine if
AsplaTAla ETB receptors had altered agonist efficacy. Similar 
to ET A receptors, recombinant ET B receptors that are stably 
expressed in CHO cells activate PLC as assessed by measure- 
ments of IP accumulation [1,30]. In the present experiments, 
treatment of COS-7 cells transiently expressing wild-type ET B 
receptors with ET-1 and ET-3 led to a concentration-dependent 
increase intracellular IP (Fig. 3A). The ECso values for the ET- 1 
and ET-3 induced-responses w re 0.2 + 0.1 nM and 0.6 + 0.4 
nM, respectively. However, both agonists failed to increase IP 
levels in COS-7 cells expressing AsplaTAla ETB receptors (Fig. 
3A). Concomitant experiments demonstrated that the level of 
specific [~25I]ET-1 binding was similar for COS-7 cells trans- 
fected with wild-type or Asp~47Ala ETB receptors, consistent 
with equivalent receptor expression (Fig. 3B). 
4. Discuss ion  
Identification of receptor amino acids involved in ligand 
binding and signal transduction is a fundamental step in eluci- 
dating ligand-receptor-G protein interactions and in under- 
Table 2 
Inhibition of specific [~251]ET-1 binding (50 pM) to Asp~47Ala, His~5°Ala, HistS°Tyr and Asp~54Ala ET B receptor mutants 
Agent Wild-type Asp147Ala His~5°Ala His Is°Tyr Asp154Ala 
ETB ETB ETB ETB ET~ 
ET-1 0.2 ± 0.0 0.1 ± 0.02 0.2 + 0.1 1.5 ± 0.1 0.1 +__ 0.02 
ET-3 0.4 ± 0.2 0.1 ± 0.03 1 + 0.1 6 ± 0.4 0.2 + 0.1 
$6c 0.3 ± 0.1 1.2 _+ 0.6 8 + 1 50 ± 4 0.1 + 0.03 
BMS- 182874 110,000 + 27,000 > 50,000 > 50,000 > 50,000 > 50,000 
Ro 47-0203 160 ± 40 95 ± 5 1,700 ± 400 700 ± 30 190 + 20 
Values are inhibition constants (IC50) in nM + S.E.M. (n = 3 6). Binding to the wild-type receptor is shown for comparison. 
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standing the mechanisms by which GPCRs transduce signals 
from the extracellular to intracellular milieux. Several recent 
studies have begun to characterize r sidues in the ET receptors 
that are involved in agonist and antagonist binding [8-12] as 
well as in defining the subtype-selective ligand binding profile 
[13-14]. Less information is presently available on specific resi- 
dues involved in signal transduction [31]. In the present study 
we demonstrate hat the aspartate residues flanking Tyr 129 of 
ETA are involved in binding and PLC activation (Asp 126) and 
that the corresponding aspartate (Asp j47) in the ETB receptor 
are involved in signaling. 
A significant finding from this study was the altered ligand 
binding profile of the Asp~26Ala ETA mutant. While we had 
recently observed a 200-fold improvement in ET-3 affinity for 
the Tyr~29Ala ETA receptor mutant [13], the observation that 
mutation of Asp 126, a residue proposed to lie 13 amino acids 
within the TM2, similarly improves ET-3 affinity was unex- 
pected. In the absence of ligand-receptor structure-activity 
data that would point clearly toward a direct ligand interaction 
with Asp 126, and because our model suggests that Asp 126 is deep 
within the transmembrane region, we must consider the possi- 
bility that Asp 126 influences binding by affecting the position of 
the Tyr 129 side chain in the binding cavity rather than by directly 
interacting with a ligand. Recently, it has been shown that 
mutation of Tyr 129 to phenylalanine [14] as well as alanine 
[13,14] causes more than a 100-fold increase in ET-3 binding. 
Since ET-3 binding improved in the Tyr129phe mutant, a direct, 
unfavorable interaction of ET-3 with the phenolic OH of the 
Tyr I29 is possible. However, in light of the present Asp126Ala 
data, another possibility is that the OH group of Zyr 129 is 
involved in specific interactions with Asp 126. According to this 
view, the interaction of Asp 126 with the phenolic OH may con- 
strain the orientation of Tyr 129. Removal of the OH group, as 
in the Tyr~29phe mutant, or mutation of Asp 126 to alanine may 
alter these constraints and allow for steric rearrangements that 
result in improved ET-3 binding. 
In contrast to ET-3, sarafotoxin $6c binding affinity to 
Asp~26Ala receptors was not improved (Table 1). Sarafotoxin 
$6c and ET-3 are 50% homologous, suggesting that one or 
more of the non-conserved amino acid residues in ET-3 is 
responsible for the improved affinity for the Asp~26Ala mutant 
receptor. In this regard, it is important to note that for both the 
Tyr129Ala nd Asp126Ala mutants, the side chains of the native 
receptor were replaced with amino acids containing side chains 
of considerably less bulk. Correspondingly, ET-3 has amino 
acids of greater steric bulk at positions 4 and 5 when compared 
to ET-1, ET-2 and sarafotoxin $6c (Phe4 and Thr 5 in ET-3 v 
Ser 4 and Ser 5 in ET-1 and ET-2 v Asn 4 and Asp 5 in sarafotoxin 
$6c). Thus, reduction in the bulk of receptor amino acids may 
contribute to the changes observed in ligand binding affinities. 
Additional experiments are necessary to precisely map the 
binding sites for the ET peptides. 
Interaction with Asp 133 of ETA receptors appears not to be 
a general requirement for conferring the well-defined subtype- 
selectivity profile since only the affinity of BMS- 182874 was 
altered in this mutant from wild-type ET A receptor values. 
Rather, it seems more likely that structural differences between 
BMS-182874 and BQ-123 lead to disparate contacts in the ETA 
receptor and that only BMS-182874 binding is dependent on 
the presence of Asp 133. It is interesting to note that the pyrim- 
idinyl naphthalenesulfonamide, Ro 474)203, which binds to 
ET A and ET s receptors with approximately equal affinity [6], 
had similar binding affinity for wild-type and AspmAla mutant 
ETA receptors. This may suggest that the decreased affinity of 
BMS-182874 for the AspmAla ETA mutant was specific for the 
ET A selective naphthalenesulfonamide series of antagonists. 
That Asp 126 and Tyr 129 [13] appear to be important for the 
high affinity binding of ET-3 and BMS-182874 is consistent 
with the hypothesis that the binding sites for agonists and 
antagonists are, at least in part, overlapping. On the other 
hand, the data showing that Asp 133 is critical only for the high 
affinity binding of BMS-182874 suggests that the binding site 
for this antagonist is also, at least in part, distinct from the 
binding site for the peptides. This is reminiscent of the observa- 
tion that agonists and antagonists bind differently to the AT1 
angiotensin II [32], cholecystokinin-B/gastrin [33], neurokinin-1 
[34- 35] and bradykinin receptors [36]. Studies in progress that 
are aimed at docking ligands into the putative binding cavities 
of the ET receptors hould yield more precise information on 
agonist and antagonist binding sites. 
Asp 126 in ET A and Asp 147 in ETB receptors correspond to the 
aspartate residue in TM2 that is conserved in many GPCR [15]. 
This conserved aspartate has been shown to play a role in 
agonist binding and transmembrane signaling via G proteins in 
the ~2-adrenergic [16], LH [17] and AT1 angiotensin II [18] 
receptors and has been implicated in the allosteric modulation 
of agonist binding in the ~2-adrenergic [37], somatostatin type 
2 [38] and serotonin receptors [39] by sodium ion. A significant 
finding from the present study was the requirement of Asp 126 
in the ET A receptor and Asp 147 in the ETB receptor for PLC 
activation. Thus, agonist efficacy did not correlate with binding 
affinity in the Asp126Ala ETA or Asp147Ala ET B mutants as high 
affinity ET-1 and ET-3 binding is better than or comparable to 
that in wild-type receptors yet stimulation of IP accumulation 
was abolished. Because of the transient nature of receptor ex- 
pression in these experiments, care was taken to concomitantly 
assess agonist binding and efficacy. In all experiments, pecifi- 
cally bound [~25I]ET-1 to mutated ETA or ETB receptors was 
equal to or slightly greater than that to the corresponding 
wild-type ET receptors demonstrating that reduced efficacy 
was not due to reduced receptor expression. At present, it is not 
clear if the receptor mutations have an effect on G protein 
coupling or whether this in turn effects agonist binding. Such 
investigation is best conducted in mammalian cell lines that 
stably express the mutant receptors rather than the transient 
expression studied here. However, high concentrations (200 
/~M) of the non-hydrolyzable guanine nucleotide, GTPTS, did 
not alter the binding affinity of ET-1 to transiently expressed 
wild-type or Asp126Ala ET A receptors (E.C-K. Liu and M.L. 
Webb, unpublished) suggesting that either most of the ETA 
receptors are already uncoupled from G-protein or that ET-1 
binding is nucleotide independent. 
In addition, the present study has demonstrated that, despite 
the 160-fold improvement in ET-3 affinity to the Asp126Ala 
mutant, the efficacy of this agonist remained ETR-like. Al- 
though the precise reason for this finding is unclear, these data 
are consistent with the suggestion that the removal or re-posi- 
tioning of residues in TM2 that led to enhanced ET-3 binding, 
possibly through localized structural changes in the Asp 126- 
Tyrl29-Asp t33 region, are different from the receptor conforma- 
tional changes that are necessary for signal transduction or- 
mally triggered by Asp 126. 
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In summary and in combination with our previous studies 
[13], the present data demonstrate that the mspt26-Tyr129-Asp 133
turn in TM2 contributes to ETA receptor subtype-selective li- 
gand binding, largely defined by Tyr J29, and to transmembrane 
signal transduction. In contrast, whereas His is° contributes to 
h Lgh affinity ET-3, sarafotoxin $6c and Ro 47-0203 binding, the 
corresponding aspartates in TM2 of the ETB receptor, Asp 147 
aad Asp j~, are not involved in defining the agonist binding 
profile. Thus, a region that is critical in defining high affinity 
ligand binding and transmembrane signaling in ETA is involved 
predominantly in signaling in ETB. 
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